Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mastocytosis, Cutaneous | 1 | 2024 | 5 | 0.910 |
Why?
|
| Skin Neoplasms | 7 | 2022 | 907 | 0.900 |
Why?
|
| Mast Cells | 1 | 2024 | 83 | 0.870 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2020 | 16 | 0.840 |
Why?
|
| Skin | 3 | 2024 | 551 | 0.820 |
Why?
|
| Skin Diseases | 3 | 2022 | 135 | 0.820 |
Why?
|
| Acanthoma | 1 | 2022 | 5 | 0.800 |
Why?
|
| Keratosis, Actinic | 1 | 2022 | 14 | 0.790 |
Why?
|
| Acrospiroma | 1 | 2020 | 5 | 0.680 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2020 | 34 | 0.670 |
Why?
|
| Melanocytes | 2 | 2022 | 50 | 0.270 |
Why?
|
| Biopsy | 4 | 2024 | 1304 | 0.260 |
Why?
|
| Carcinosarcoma | 2 | 2015 | 12 | 0.230 |
Why?
|
| Tryptases | 1 | 2024 | 20 | 0.230 |
Why?
|
| Dermatitis | 1 | 2024 | 26 | 0.220 |
Why?
|
| Urticaria | 1 | 2024 | 22 | 0.220 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 1720 | 0.210 |
Why?
|
| Myofibrils | 1 | 2003 | 27 | 0.210 |
Why?
|
| Head and Neck Neoplasms | 2 | 2020 | 699 | 0.210 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 1070 | 0.200 |
Why?
|
| MART-1 Antigen | 1 | 2022 | 14 | 0.200 |
Why?
|
| SOXE Transcription Factors | 1 | 2022 | 15 | 0.200 |
Why?
|
| Schwann Cells | 1 | 2002 | 68 | 0.190 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 10 | 0.180 |
Why?
|
| Myoclonus | 1 | 2021 | 34 | 0.180 |
Why?
|
| Scalp | 2 | 2020 | 59 | 0.180 |
Why?
|
| Hidrocystoma | 1 | 2020 | 4 | 0.170 |
Why?
|
| Apocrine Glands | 1 | 2020 | 4 | 0.170 |
Why?
|
| Colonic Neoplasms | 1 | 2003 | 271 | 0.170 |
Why?
|
| Encephalitis | 1 | 2021 | 121 | 0.170 |
Why?
|
| Melanoma | 2 | 2008 | 975 | 0.160 |
Why?
|
| Barrett Esophagus | 1 | 2003 | 355 | 0.150 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 393 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 718 | 0.140 |
Why?
|
| Cryoglobulinemia | 1 | 2017 | 11 | 0.140 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2017 | 68 | 0.140 |
Why?
|
| Genome, Human | 2 | 2015 | 1350 | 0.140 |
Why?
|
| Penis | 1 | 2017 | 102 | 0.130 |
Why?
|
| Heart | 1 | 2001 | 749 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 169 | 0.120 |
Why?
|
| Myocardium | 1 | 2001 | 1045 | 0.120 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2014 | 25 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 1334 | 0.110 |
Why?
|
| Humans | 17 | 2024 | 133937 | 0.110 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2014 | 64 | 0.110 |
Why?
|
| Middle Aged | 4 | 2024 | 29409 | 0.110 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 178 | 0.100 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2012 | 4 | 0.100 |
Why?
|
| Dermatomycoses | 1 | 2012 | 18 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 648 | 0.090 |
Why?
|
| Aged | 4 | 2024 | 21746 | 0.090 |
Why?
|
| Mutation | 2 | 2015 | 6296 | 0.080 |
Why?
|
| Male | 6 | 2024 | 65902 | 0.080 |
Why?
|
| Young Adult | 1 | 2024 | 9889 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2008 | 13 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2003 | 1761 | 0.070 |
Why?
|
| Adult | 4 | 2024 | 31949 | 0.070 |
Why?
|
| Female | 9 | 2024 | 71682 | 0.070 |
Why?
|
| Lupus Nephritis | 1 | 2007 | 43 | 0.070 |
Why?
|
| Adolescent | 2 | 2024 | 20534 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2024 | 17488 | 0.060 |
Why?
|
| Nevus | 1 | 2005 | 36 | 0.060 |
Why?
|
| Connective Tissue Diseases | 1 | 2005 | 33 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 589 | 0.060 |
Why?
|
| Hamartoma | 1 | 2005 | 53 | 0.060 |
Why?
|
| Child | 1 | 2024 | 25739 | 0.050 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2003 | 7 | 0.050 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 2002 | 6 | 0.050 |
Why?
|
| Muscle, Smooth | 1 | 2003 | 138 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 104 | 0.050 |
Why?
|
| Neural Crest | 1 | 2002 | 56 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2001 | 119 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 2001 | 57 | 0.040 |
Why?
|
| Cadaver | 1 | 2001 | 141 | 0.040 |
Why?
|
| Actins | 1 | 2003 | 351 | 0.040 |
Why?
|
| Pigmentation | 1 | 2020 | 37 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2001 | 188 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 548 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 2122 | 0.040 |
Why?
|
| Cell Division | 1 | 2001 | 774 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2002 | 644 | 0.040 |
Why?
|
| CREST Syndrome | 1 | 2017 | 4 | 0.040 |
Why?
|
| Ecchymosis | 1 | 2017 | 12 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1977 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2017 | 44 | 0.040 |
Why?
|
| Purpura | 1 | 2017 | 26 | 0.040 |
Why?
|
| Patient Care Management | 1 | 2017 | 68 | 0.030 |
Why?
|
| Gestational Age | 1 | 2001 | 1217 | 0.030 |
Why?
|
| Body Weight | 1 | 2001 | 1034 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 376 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2017 | 188 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 7212 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 248 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2008 | 62 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2001 | 8591 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 5081 | 0.020 |
Why?
|
| Hyperpigmentation | 1 | 2007 | 13 | 0.020 |
Why?
|
| Hydroxychloroquine | 1 | 2007 | 21 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2008 | 201 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 2007 | 124 | 0.020 |
Why?
|
| Fibrosis | 1 | 2007 | 461 | 0.020 |
Why?
|
| Collagen | 1 | 2005 | 334 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 3167 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 2539 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 7522 | 0.010 |
Why?
|